Marksans Pharma Overview
- Founded
-
1992
- Status
-
Public
- Employees
-
890
- Stock Symbol
-
MARKSANS
- Investments
-
6
- Share Price
-
$0.76
- (As of Wednesday Closing)
Marksans Pharma General Information
Description
Marksans Pharma Ltd is a pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical formulations. It manufactures analgesics, expectorants, anti-diabetic, cardiovascular, central nervous system, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. The company also offers Contract Research and Manufacturing Services (CRAMS) to pharmaceutical companies. It has a global market presence with the majority of the revenue generated from North America, Europe, and the United Kingdom.
Contact Information
Primary Industry
Drug Discovery
Stock Exchange
NSE
Primary Office
- 11th Floor, Grandeur
- Veera Desai Extension Road, Oshiwara, Andheri West
- Mumbai, Maharashtra 400053
- India
+91 022 0000 0000
Marksans Pharma Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.76 | $0.79 | $0.50 - $0.86 | $339M | 447M | 2.68M | $0.06 |
Marksans Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 202,114 | 209,340 | 262,268 | 80,741 |
| Revenue | 215,716 | 198,654 | 183,921 | 158,948 |
| EBITDA | 42,145 | 39,151 | 45,783 | 26,559 |
| Net Income | 25,904 | 25,073 | 32,062 | 16,995 |
| Total Assets | 204,735 | 216,291 | 167,310 | 119,686 |
| Total Debt | 12,320 | 14,609 | 4,643 | 3,931 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Marksans Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Marksans Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Marksans Pharma Ltd is a pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical form
Drug Discovery
Mumbai, India
890
As of 2022
0000
000000
dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
000000000000000
Mumbai, India
00
As of 0000
00.000
00000000000
00.000
000000
etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
000000000000000
Noida, India
0000
As of 0000
00000
0000
0000-00-00
00000000000
00000
Add Comparison
Marksans Pharma Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis India | Corporation | Mumbai, India | 00 | 00.000 | 00000000000 | 00.000 |
| 00000000 00000000 | Corporation | Noida, India | 0000 | 00000 | 00000000000 | 00000 |
| 00000 | Corporation | Mumbai, India | 00000 | 00000000 | ||
| 000000 | Formerly PE-Backed | Bengaluru, India | 00000 | 000.00 | 00000000 | 000.00 |
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 |
Marksans Pharma Patents
Marksans Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220079894-A1 | Stable pharmaceutical compositions | Pending | 11-Sep-2020 | 0000000000 |
Marksans Pharma Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mark Saldanha | Founder Promoter, Chairman, Managing Director & Chief Executive Officer | ||
| Jitendra Sharma | Chief Financial Officer |
Marksans Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Marksans Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Marksans Pharma Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 (00 | 11-Oct-2022 | 0000000000 | Pharmaceuticals | 0000 0000 | |
| 000000 000000 | 06-Jun-2022 | 0000000000 | 00.000 | Media and Information Services (B2B) | 0000 0000 |
| 0000-000 0000 | 30-Jun-2015 | 0000000000 | 0000 | Pharmaceuticals | 0000 0000 |
| 000000000 | 28-Aug-2008 | 0000000000 | 000.00 | Distributors/Wholesale | 0000 0000 |
| Hale Group | 18-Jan-2008 | Merger/Acquisition | Holding Companies | 0000 0000 |
Marksans Pharma Subsidiaries (4)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Nova Pharmaceuticals Australasia | Drug Discovery | Australia | 2003 |
| 000000000 | Distributors/Wholesale | Widnes, United Kingdom | 0000 |
| 0000-000 0000 | Pharmaceuticals | Farmingdale, NY | 0000 |
| 000000 0000000000 | Media and Information Services (B2B) | Dubai, United Arab Emirates |
Marksans Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Marksans Pharma Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 00000 | 18-Jan-2008 | 000000000000000000 | Completed |
|